<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p175" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_175{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_175{left:306px;bottom:30px;}
#t3_175{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_175{left:346px;bottom:30px;}
#t5_175{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_175{left:517px;bottom:30px;}
#t7_175{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_175{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_175{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_175{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_175{left:35px;bottom:777px;letter-spacing:0.11px;word-spacing:0.08px;}
#tc_175{left:35px;bottom:754px;letter-spacing:0.07px;word-spacing:0.11px;}
#td_175{left:35px;bottom:731px;letter-spacing:0.11px;word-spacing:0.07px;}
#te_175{left:35px;bottom:707px;letter-spacing:0.1px;word-spacing:-0.92px;}
#tf_175{left:35px;bottom:684px;letter-spacing:0.12px;word-spacing:0.06px;}
#tg_175{left:35px;bottom:645px;letter-spacing:0.14px;word-spacing:0.05px;}
#th_175{left:35px;bottom:622px;letter-spacing:0.1px;word-spacing:0.09px;}
#ti_175{left:35px;bottom:599px;letter-spacing:0.22px;word-spacing:-0.03px;}
#tj_175{left:270px;bottom:599px;letter-spacing:0.25px;word-spacing:-0.07px;}
#tk_175{left:35px;bottom:575px;letter-spacing:0.05px;word-spacing:-0.81px;}
#tl_175{left:550px;bottom:583px;letter-spacing:0.1px;}
#tm_175{left:35px;bottom:552px;letter-spacing:0.12px;word-spacing:0.08px;}
#tn_175{left:35px;bottom:529px;letter-spacing:0.09px;word-spacing:-0.77px;}
#to_175{left:35px;bottom:506px;letter-spacing:0.01px;word-spacing:0.17px;}
#tp_175{left:35px;bottom:482px;letter-spacing:0.16px;word-spacing:0.02px;}
#tq_175{left:35px;bottom:459px;letter-spacing:0.16px;word-spacing:0.03px;}
#tr_175{left:35px;bottom:436px;letter-spacing:0.04px;word-spacing:0.15px;}
#ts_175{left:35px;bottom:413px;letter-spacing:0.11px;word-spacing:-0.91px;}
#tt_175{left:35px;bottom:390px;letter-spacing:0.14px;word-spacing:0.04px;}
#tu_175{left:35px;bottom:349px;letter-spacing:0.17px;word-spacing:-0.29px;}
#tv_175{left:35px;bottom:326px;letter-spacing:0.07px;word-spacing:-0.93px;}
#tw_175{left:35px;bottom:303px;letter-spacing:0.13px;word-spacing:0.06px;}
#tx_175{left:35px;bottom:280px;letter-spacing:-0.03px;word-spacing:-0.66px;}
#ty_175{left:35px;bottom:256px;letter-spacing:0.22px;word-spacing:-1.27px;}
#tz_175{left:138px;bottom:264px;letter-spacing:-0.01px;}
#t10_175{left:203px;bottom:256px;letter-spacing:0.15px;word-spacing:-0.21px;}
#t11_175{left:35px;bottom:233px;letter-spacing:0.07px;word-spacing:-0.98px;}
#t12_175{left:35px;bottom:210px;letter-spacing:0.12px;word-spacing:0.06px;}
#t13_175{left:35px;bottom:187px;letter-spacing:0.21px;word-spacing:-0.03px;}
#t14_175{left:35px;bottom:163px;letter-spacing:0.15px;word-spacing:0.04px;}
#t15_175{left:35px;bottom:140px;letter-spacing:0.09px;word-spacing:0.1px;}
#t16_175{left:252px;bottom:140px;letter-spacing:0.26px;word-spacing:-0.07px;}
#t17_175{left:447px;bottom:140px;letter-spacing:0.1px;word-spacing:0.08px;}
#t18_175{left:35px;bottom:117px;letter-spacing:-0.31px;}
#t19_175{left:68px;bottom:117px;letter-spacing:0.21px;word-spacing:-1.25px;}
#t1a_175{left:269px;bottom:117px;letter-spacing:0.05px;word-spacing:-1.09px;}
#t1b_175{left:35px;bottom:94px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1c_175{left:35px;bottom:71px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1d_175{left:618px;bottom:777px;letter-spacing:0.02px;word-spacing:0.17px;}
#t1e_175{left:618px;bottom:754px;letter-spacing:0.02px;word-spacing:0.17px;}
#t1f_175{left:618px;bottom:731px;letter-spacing:0.07px;word-spacing:-1.12px;}
#t1g_175{left:618px;bottom:707px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1h_175{left:618px;bottom:684px;letter-spacing:0.07px;word-spacing:-1.12px;}
#t1i_175{left:618px;bottom:661px;letter-spacing:0.16px;word-spacing:0.02px;}
#t1j_175{left:618px;bottom:638px;letter-spacing:0.02px;word-spacing:-1.07px;}
#t1k_175{left:618px;bottom:614px;letter-spacing:0.22px;word-spacing:-0.03px;}
#t1l_175{left:618px;bottom:591px;letter-spacing:0.04px;}
#t1m_175{left:618px;bottom:552px;letter-spacing:0.01px;word-spacing:-1.05px;}
#t1n_175{left:618px;bottom:529px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1o_175{left:618px;bottom:506px;letter-spacing:0.15px;word-spacing:0.04px;}
#t1p_175{left:618px;bottom:482px;letter-spacing:0.17px;word-spacing:0.02px;}
#t1q_175{left:862px;bottom:482px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1r_175{left:618px;bottom:459px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1s_175{left:618px;bottom:436px;letter-spacing:0.08px;word-spacing:0.1px;}
#t1t_175{left:618px;bottom:413px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1u_175{left:813px;bottom:420px;letter-spacing:0.1px;}
#t1v_175{left:618px;bottom:374px;letter-spacing:-0.11px;word-spacing:0.53px;}
#t1w_175{left:618px;bottom:350px;letter-spacing:0.17px;word-spacing:0.01px;}
#t1x_175{left:618px;bottom:327px;letter-spacing:0.05px;word-spacing:-0.69px;}
#t1y_175{left:880px;bottom:335px;letter-spacing:0.1px;}
#t1z_175{left:925px;bottom:327px;letter-spacing:0.13px;word-spacing:0.06px;}
#t20_175{left:618px;bottom:304px;letter-spacing:0.09px;word-spacing:-0.98px;}
#t21_175{left:618px;bottom:281px;letter-spacing:0.15px;word-spacing:0.04px;}
#t22_175{left:618px;bottom:258px;letter-spacing:0.17px;word-spacing:-0.29px;}
#t23_175{left:618px;bottom:234px;letter-spacing:0.12px;word-spacing:0.07px;}
#t24_175{left:618px;bottom:211px;letter-spacing:0.01px;word-spacing:0.18px;}
#t25_175{left:618px;bottom:188px;letter-spacing:0.08px;word-spacing:0.11px;}
#t26_175{left:970px;bottom:195px;letter-spacing:0.1px;}
#t27_175{left:1016px;bottom:188px;letter-spacing:0.16px;word-spacing:0.03px;}
#t28_175{left:618px;bottom:165px;letter-spacing:0.07px;word-spacing:0.12px;}
#t29_175{left:618px;bottom:141px;letter-spacing:0.14px;word-spacing:0.05px;}
#t2a_175{left:840px;bottom:149px;letter-spacing:0.1px;}
#t2b_175{left:885px;bottom:141px;letter-spacing:0.17px;word-spacing:0.02px;}
#t2c_175{left:618px;bottom:118px;letter-spacing:0.15px;word-spacing:0.04px;}
#t2d_175{left:618px;bottom:95px;letter-spacing:0.11px;word-spacing:0.08px;}
#t2e_175{left:835px;bottom:95px;letter-spacing:0.21px;word-spacing:-0.02px;}
#t2f_175{left:618px;bottom:72px;letter-spacing:0.17px;word-spacing:-1.21px;}
#t2g_175{left:763px;bottom:72px;letter-spacing:0.12px;word-spacing:-0.08px;}
#t2h_175{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_175{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_175{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_175{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_175{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_175{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_175{font-size:17px;font-family:ArialMT_k0;color:#000;}
.s6_175{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s7_175{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s8_175{font-size:16px;font-family:Arial-BoldItalicMT_kg;color:#000;}
.s9_175{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts175" type="text/css" >

@font-face {
	font-family: Arial-BoldItalicMT_kg;
	src: url("fonts/Arial-BoldItalicMT_kg.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

</style>
<div id="pg175Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg175" style="-webkit-user-select: none;"><object width="1210" height="935" data="175/175.svg" type="image/svg+xml" id="pdf175" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_175" class="t s0_175">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_175" class="t s1_175">© </span>
<span id="t3_175" class="t s0_175">(NCCN </span>
<span id="t4_175" class="t s1_175">© </span>
<span id="t5_175" class="t s0_175">), All rights reserved. NCCN Guidelines </span>
<span id="t6_175" class="t s1_175">® </span>
<span id="t7_175" class="t s0_175">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_175" class="t s2_175">NCCN Guidelines Version 4.2024 </span>
<span id="t9_175" class="t s2_175">Head and Neck Cancers </span>
<span id="ta_175" class="t s3_175">MS-34 </span>
<span id="tb_175" class="t s4_175">N1 disease. However, this is a category 2B option, since the number of </span>
<span id="tc_175" class="t s4_175">patients with T1–T2, N1 disease enrolled in the GORTEC trial is small, </span>
<span id="td_175" class="t s4_175">and more data from prospective trials are needed. For patients with p16- </span>
<span id="te_175" class="t s4_175">positive disease, systemic therapy/RT is also a category 2B option for T0– </span>
<span id="tf_175" class="t s4_175">T2 disease and the involvement of a single node 3 cm or less. </span>
<span id="tg_175" class="t s4_175">For locally advanced resectable disease (T3–4a, N0–1, or N2–3 for p16- </span>
<span id="th_175" class="t s4_175">negative disease; T0–2, cN1 [single node &gt;3 cm, or 2 or more ipsilateral </span>
<span id="ti_175" class="t s5_175">nodes ≤6 cm] or N2, or T3, N0</span><span id="tj_175" class="t s4_175">–3, or T4 for p16-positive disease), </span>
<span id="tk_175" class="t s4_175">treatment recommendations include concurrent systemic therapy/RT </span>
<span id="tl_175" class="t s6_175">151,181 </span>
<span id="tm_175" class="t s4_175">and resection of the primary and neck dissection (with appropriate </span>
<span id="tn_175" class="t s4_175">adjuvant therapy [systemic therapy/RT or RT]), in addition to enrollment in </span>
<span id="to_175" class="t s4_175">clinical trials. As with early-stage disease, tumors at or approaching the </span>
<span id="tp_175" class="t s4_175">midline should be strongly considered for bilateral treatment of the neck. </span>
<span id="tq_175" class="t s4_175">The panel asserts that concurrent systemic therapy/RT is preferred in </span>
<span id="tr_175" class="t s4_175">patients with locoregionally advanced HPV-positive disease who have </span>
<span id="ts_175" class="t s4_175">clinical evidence of fixed or matted nodes or obvious extranodal extension </span>
<span id="tt_175" class="t s4_175">in patients, as surgery is not recommended for these patients. </span>
<span id="tu_175" class="t s4_175">Induction chemotherapy (followed by RT or systemic therapy/RT, though </span>
<span id="tv_175" class="t s4_175">surgery may be an option in very select patients with disease that does not </span>
<span id="tw_175" class="t s4_175">respond to induction chemotherapy) is listed as a treatment option for </span>
<span id="tx_175" class="t s4_175">patients with locally advanced resectable oropharyngeal cancer regardless </span>
<span id="ty_175" class="t s4_175">of p16 status, </span>
<span id="tz_175" class="t s6_175">112,115,460 </span>
<span id="t10_175" class="t s4_175">but is a category 3 option due to lack of consensus </span>
<span id="t11_175" class="t s4_175">among NCCN Member Institutions. Panel concerns are based on absence </span>
<span id="t12_175" class="t s4_175">of benefit of induction chemotherapy in randomized clinical trials and </span>
<span id="t13_175" class="t s4_175">concerns that use of better-tolerated—but potentially less effective— </span>
<span id="t14_175" class="t s4_175">concurrent regimens or poorer patient adherence with RT may </span>
<span id="t15_175" class="t s4_175">compromise outcomes (see </span><span id="t16_175" class="t s7_175">Induction Chemotherapy </span><span id="t17_175" class="t s4_175">in this Discussion, </span>
<span id="t18_175" class="t s4_175">and </span><span id="t19_175" class="t s7_175">Cancer of the Oropharynx </span><span id="t1a_175" class="t s4_175">in the NCCN Guidelines for Head and Neck </span>
<span id="t1b_175" class="t s4_175">Cancers). Patients with p16-positive cN2–3 disease who are treated with </span>
<span id="t1c_175" class="t s4_175">initial surgery have a high likelihood of extranodal extension, which </span>
<span id="t1d_175" class="t s4_175">warrants adjuvant systemic therapy/RT treatment. Triple modality </span>
<span id="t1e_175" class="t s4_175">management is associated with increased toxicity. Beginning treatment </span>
<span id="t1f_175" class="t s4_175">with concurrent systemic therapy/RT may help decrease the need for triple </span>
<span id="t1g_175" class="t s4_175">modality therapy and additional treatment-induced morbidity. Therefore, </span>
<span id="t1h_175" class="t s4_175">definitive concurrent systemic therapy/RT is preferred over upfront surgery </span>
<span id="t1i_175" class="t s4_175">for p16-positive cT4 or cN3 oropharyngeal cancer. Panel </span>
<span id="t1j_175" class="t s4_175">recommendations regarding adjuvant therapy for locally advanced disease </span>
<span id="t1k_175" class="t s4_175">do not differ between p16-positive and p16-negative oropharyngeal </span>
<span id="t1l_175" class="t s4_175">cancer. </span>
<span id="t1m_175" class="t s4_175">Concurrent systemic therapy/RT—with high-dose cisplatin as the preferred </span>
<span id="t1n_175" class="t s4_175">systemic agent—is recommended for treatment of locoregionally </span>
<span id="t1o_175" class="t s4_175">advanced p16-positive and p16-negative cancer of the oropharynx (see </span>
<span id="t1p_175" class="t s7_175">Principles of Systemic Therapy </span><span id="t1q_175" class="t s4_175">in the NCCN Guidelines for Head and </span>
<span id="t1r_175" class="t s4_175">Neck Cancers). Evidence from multiple prospective trials in HPV-positive </span>
<span id="t1s_175" class="t s4_175">oropharyngeal cancer demonstrates that cetuximab and RT is inferior to </span>
<span id="t1t_175" class="t s4_175">cisplatin (in terms of OS). </span>
<span id="t1u_175" class="t s6_175">285,286 </span>
<span id="t1v_175" class="t s8_175">Radiation Therapy Fractionation </span>
<span id="t1w_175" class="t s4_175">IMRT is preferred for radiation treatment of oropharynx cancer, as it is </span>
<span id="t1x_175" class="t s4_175">associated with decreased toxicity. </span>
<span id="t1y_175" class="t s6_175">461,462 </span>
<span id="t1z_175" class="t s4_175">There is an ongoing randomized </span>
<span id="t20_175" class="t s4_175">trial comparing IMRT with IMPT in oropharyngeal cancer (NCT01893307). </span>
<span id="t21_175" class="t s4_175">A fractionation schedule of 66–70 Gy at 2 Gy/fraction daily (Monday– </span>
<span id="t22_175" class="t s4_175">Friday) for 6 to 7 weeks is recommended for patients with gross disease. </span>
<span id="t23_175" class="t s4_175">Hypofractionation, hyperfractionation, or accelerated fractionation is </span>
<span id="t24_175" class="t s4_175">acceptable in patients with early-stage oropharyngeal cancer and may be </span>
<span id="t25_175" class="t s4_175">associated with improved locoregional control. </span>
<span id="t26_175" class="t s6_175">151,157 </span>
<span id="t27_175" class="t s4_175">For elective nodal </span>
<span id="t28_175" class="t s4_175">treatment, a biologically equivalent dose of approximately 40–50 Gy in 2 </span>
<span id="t29_175" class="t s4_175">Gy/fraction is recommended. </span>
<span id="t2a_175" class="t s6_175">151,463 </span>
<span id="t2b_175" class="t s4_175">The complete list of recommended </span>
<span id="t2c_175" class="t s4_175">schedules for radiation treatment of p16-positive oropharynx cancer are </span>
<span id="t2d_175" class="t s4_175">shown in the algorithm (see </span><span id="t2e_175" class="t s7_175">Cancer of the Oropharynx: Principles of </span>
<span id="t2f_175" class="t s7_175">Radiation Therapy </span><span id="t2g_175" class="t s4_175">in the NCCN Guidelines for Head and Neck Cancers). </span>
<span id="t2h_175" class="t s9_175">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
